{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:20:00Z","timestamp":1793262000459,"version":"4.5.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:00:00Z","timestamp":1584662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.jacl.2020.03.001","type":"journal-article","created":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T16:13:14Z","timestamp":1585411994000},"page":"322-330.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study"],"prefix":"10.1016","volume":"14","author":[{"given":"Stephen","family":"Daniels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Caprio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5491-1032","authenticated-orcid":false,"given":"Garen","family":"Manvelian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie T.","family":"Baccara-Dinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5541-2083","authenticated-orcid":false,"given":"Aurelie","family":"Brunet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Scemama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Loizeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Bruckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2020.03.001_bib1","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3390\/jcm8071080","article-title":"Incidence of cardiovascular disease in patients with familial hypercholesterolemia phenotype: analysis of 5 years follow-up of real-world data from more than 1.5 million patients","volume":"8","author":"Masana","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacl.2020.03.001_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.atherosclerosis.2018.01.040","article-title":"Lipoprotein profile assessed by 2D-1H-NMR and subclinical atherosclerosis in children with familial hypercholesterolaemia","volume":"270","author":"Rodriguez-Borjabad","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2020.03.001_bib3","doi-asserted-by":"crossref","first-page":"e0158964","DOI":"10.1371\/journal.pone.0158964","article-title":"Carotid and aortic stiffness in patients with heterozygous familial hypercholesterolemia","volume":"11","author":"Ershova","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jacl.2020.03.001_bib4","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-year follow-up of statins in children with familial hypercholesterolemia","volume":"381","author":"Luirink","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2020.03.001_bib5","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2020.03.001_bib6","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2020.03.001_bib7","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2020.03.001_bib8","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jacl.2019.10.004","article-title":"Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses","volume":"13","author":"Robinson","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2020.03.001_bib9","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMc1616623","article-title":"Antidrug antibodies in patients treated with alirocumab","volume":"376","author":"Roth","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2020.03.001_bib10","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.amjcard.2016.08.072","article-title":"Safety of alirocumab (a PCSK9 monoclonal antibody) from 14 randomized trials","volume":"118","author":"Jones","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2020.03.001_bib11","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S2213-8587(19)30158-5","article-title":"Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial","volume":"7","author":"Ray","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacl.2020.03.001_bib12","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1111\/dme.13817","article-title":"Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials","volume":"35","author":"Leiter","year":"2018","journal-title":"Diabet Med"},{"key":"10.1016\/j.jacl.2020.03.001_bib13","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1093\/eurheartj\/ehw292","article-title":"No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies","volume":"37","author":"Colhoun","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2020.03.001_bib14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4330\/wjc.v9.i2.76","article-title":"PCSK9 inhibitors: a new era of lipid lowering therapy","volume":"9","author":"Chaudhary","year":"2017","journal-title":"World J Cardiol"}],"updated-by":[{"DOI":"10.1016\/j.jacl.2020.08.011","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000}}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287420300441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287420300441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T05:11:15Z","timestamp":1591679475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287420300441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S1933287420300441"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2020.03.001","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.jacl.2020.08.011","asserted-by":"object"}]},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2020.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 National Lipid Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}